Member Info for Soupdragon78

Anyhow, since the sp apparently doesn't matter and its all about 'the story'... I've been wasting a bit of time and effort looking for the story around for potential NXP004 originators.

Its all speculative, but hey... it passes the time.

So, looking at the historic RNS's for clues our first introduction to NXP004 was in the placing announcement of November 2019.

"NXP004 is a new breakthrough entry to the Nuformix pipeline and is based on a recently approved targeted oncology therapy currently experiencing significant sales growth."

So the key take away there is that it was '....recently approved..." i.e. within a year or two and that it is a '...targeted oncology therapy.' meaning it blocks the growth and spread of cancer by interfering with specific molecules ("molecular targets") that are involved in the growth, progression, and spread of cancer. Then finally '....significant sales growth' which is self explanatory.

So, with that in mind the other key factors are...

"...its formulation and side-effects have posed a significant challenge to extending the use of the drug into new indications that could also benefit from its mechanism of action. "

"· NXP004 showed a dose-dependent reduction in the secretion of several key ECM components"

"....oncology drug that has significant sales (more than £1 billion per annum in 2020) and is showing further growth."

So.... as I said looking around for what might fit these categories. At the minute I'm looking towards AstraZeneca's Lynparza (Olaparib is the drug name)

It gained FDA approval in 2017 - 'recently approved'
It had sales of $1.77bn (£1.3bn) sales for 2020 full year. - around the valuation quoted by NFX
Sales growth of 38% for 2020 - fast growing
Its a targeted oncology drug as it is a PARP inhibitor
Side effects - 60%+ users suffer from side effects. Its also suspected to cause a type of pneumopathy.
PARP inhibitor drugs are also now being looked at for IPF.
Lynparza patent runs out in 2024 so ripe for a reworking that can renew it.

Astrazeneca bought Olparib at an early stage by buying up Cambridge based KuDos Pharma for £150m in 2005, although they did get other drugs as well and the 75 staff.

So possibly Lynparza is the basis for NXP004, but what do I know.

In endless optimism that they may get something right here, I'm hoping that since they have been testing NXP004 for a number of months, this has allowed NFX to get their ducks in a row to be swift following any positive results.

We know that the cocrystal is based on a £1bn p.a. selling oncology drug and they could potentially extend its patent through to 2040.

So I hope that JH has been active of setting up the patent for filing swiftly and contact made with the originator. If Anne wants her bonus, here is her opportunity.

Extending the patent life of a £1bn drug..... = £££££

Q4, I'm hopeful that news on NXP004 will come in the near term, they've been underway with the further research since May.

" While there is literature data and preliminary preclinical data generated by the Company providing evidence for this drug's potential activity in fibrosis, it is the Company's strategy that in order to derive most value from the NXP004 asset, the opportunities in oncology should be exploited as a priority.

Should the further research be positive, there are two potential options for licensing the Company's IP to generate value from NXP004:

-- license to the originator of the marketed drug to potentially extend its patent protection, thus potentially adding significant value for the originator; or

-- license to generic companies to potentially allow commercialisation of a generic alternative to the marketed drug."

Don't worry filter, someone keeps buying 2 quids worth at a time. That'll prop the sp up.

Agree SSM, feels like we’ve been played by the pump and dump brigade over the year.
Certainly everyone who paid for the shares they hold is sitting on a loss right now.
(I say paid, as DG and JH didn’t so will still be in the blue on theirs)

Wonder what happened to that twitter poster called Make England Great @NFXupupup, he had some great posts last year... there's been some great characters but for some reason they all disappear.

"@NFXupupup Jul 24
#nfx its lined up to close NXP002 shortly. You would never state progress into next trial without confirmation in house of a deal. It looks very much like all systems are go and the formalities of the deal closed imminently. "

It could be done in an informal way. e.g. there had been talks that were left in a position of 'come back to us once you've got results', so not agreement in place other than the door is still open.

The problem is now with Riddells purchase last week. If anything positive had come of the 'business development' he could not have made his buy.

10 March

"NXP002 Asia discussions: The Board is disappointed that previous business development activities in Asia have not reached a positive conclusion. A new business development consultant has been engaged to assess the viability of legacy discussions coming to a successful conclusion in the near to medium term."

oh well... I'm just reminiscing about the time we were in talks with 'multiple' parties on NXP002. Happy days.

"Nuformix is putting in place the team and development partnerships to pursue this path for NXP002. Funds from the Placing will allow Nuformix to drive progress in this programme and support Nuformix's position in the Group's on-going discussions with multiple potential development partners in Asia and the US."

Unfortunately when the markets have a good day, NFX goes down and when the markets have a bad day, NFX goes down.

On the incentives side, its only Brindley who gets a share of a deal, which given it took 6 months for her to close out the Ox deal means she's not going to close out anything else.
Its just about data now.

Filter, I was kind of expecting NXP001 to 'add value and generate interest', I guess I was being too hopeful.

They need to let Allenby provide an update note regardless of how low the Oxilio deal figures may be. Its not a good look to not allow your broker to comment on a global licencing deal.

Just need these sellers to eff-off!

Lol! 0.0135p!!!

Good old consistent NFX, the personnel may change, but they will always make an error on whatever RNS they issue!

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that today the Company received notice that Dr Alastair Riddell, Chairman of the Company, purchased 350,000 ordinary shares of 0.1 pence each ("Ordinary Shares") at a price of 0.0135 pence per share on 16 September 2021.

Sorry chab, can't help there. I've never been able to find such a connection, I could only assume it was Yaxley and Blackwell who will have known each other through Premier and Vectura backgrounds.
The only other one I know of is that Yaxley lived next door to George Michael. Not sure if thats significant?

Nothing yet on that Mafuta, couldn't find a function to make the request so I've sent an email to the support at investormeet as to how its meant to work.

Mafuta, the issue is not so much about their cash level, they must have some kind of backing that we can't see to be able to confidently progress their lines.

My concern at the minute is that NFX is looking very weak and I don't want some cheeky company to try and take it from under us for a low ball price.
This is partly my disappointment with the radio silence from the company this week. I think they should be a bit more proactive in trying to support the sp as everyone who holds is underwater at the minute.